Topic: colorectal cancer

The startup posted initial clinical data that suggest MRTX849 can hold its own against Amgen’s rival cancer drug.

Exact Sciences and the Mayo Clinic launched a real-world study that aims to enroll at least 150,000 people to track the impact of Cologuard.

Two months after announcing its KRAS inhibitor shrank lung tumors at ASCO, Amgen reported the drug did the same in colorectal and appendiceal cancers.

Former FierceMedTech Fierce 15 winner Freenome has raised $160 million for its blood-based “multiomics” tests for the early detection of cancer.

Blocking a protein called ATF4 in tumors driven by the gene MYC causes so much stress to cancer cells that they die, Penn researchers found.

It’s been 30 years in the making, but the first clinical data from a KRAS inhibitor is finally here.

The data show early signs of efficacy, with one-third of the heavily pretreated lung cancer patients enrolled in the trial having partial responses.

FogPharma has hired Howard Stern, M.D., Ph.D., as its new chief scientific officer and Peter Fekkes, Ph.D., as VP of discovery bioscience.

Exact Sciences is seeing benefits and drawbacks since it kicked off a sales partnership with Pfizer late last year to promote its Cologuard test.

A multi-institution research team has made several surprising discoveries about the role of proteins in colon cancer, which could inspire new treatments.